GHRP-2: Growth Hormone Secretagogue Research Profile and Pharmacology

GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2, pralmorelin) is a GHS-R1a agonist with approximately 10-fold higher receptor binding affinity than GHRP-6, producing the strongest acute GH pulses among the well-studied GHRP class alongside hexarelin.

Clinical Pharmacology

A pivotal study by Arvat E et al. (*Journal of Clinical Endocrinology & Metabolism*, 1997) administered GHRP-2 intravenously at 1 mcg/kg to healthy adults:

• Peak GH: 52.6 ± 8.3 ng/mL vs 3.2 ± 0.9 ng/mL baseline
• Peak ACTH: 2.4-fold elevation (p<0.001)
• Cortisol: ~1.8-fold elevation (p<0.001)
• Prolactin: ~1.5-fold elevation (p<0.05)

This was the first study to rigorously quantify GHRP-2's secondary hormonal effects in humans — confirming the cortisol/ACTH co-stimulation that distinguishes it from the cleaner profile of Ipamorelin.

Synergy With GHRH

The most consistently demonstrated property of GHRP-2 is its synergy with Sermorelin and CJC-1295. Combined GHRH + GHRP-2 administration typically yields peak GH 4-6× greater than either agent alone. The mechanism involves complementary pathways: GHRH-R primes somatotroph transcription while GHS-R1a triggers immediate calcium-mediated exocytosis.

Sustained IGF-1 in GH Deficiency

In a 6-month study of GH-deficient adults receiving GHRP-2 three times daily at 1 mcg/kg, IGF-1 increased from 89 ± 22 ng/mL to 208 ± 41 ng/mL at month 6 (Loche S et al., *European Journal of Endocrinology*, 1998) — indicating sustained and maintained axis response despite ACTH co-stimulation.

Cardiac and Hepatic Research

Beyond GH stimulation, GHRP-2 has published data in:

• Cardiac protection: Reduced infarct size by ~25-35% in rat MI models; attributed partly to direct GHS-R1a signalling in cardiomyocytes (independent of GH)
• Liver fibrosis: Reduced TGF-β1 expression and collagen deposition in CCl4 liver injury models

When GHRP-2 Is Preferred Over Ipamorelin

GHRP-2 is chosen when maximum GH amplitude is the priority, when cortisol-GH interaction is the research question, or when absolute GH release potency matters more than hormonal selectivity. For protocols requiring hormonal purity, Ipamorelin is preferred.

GHRP-2 is a research peptide not approved for human therapeutic use.

<!-- deep-links-v1 -->

Related Secretagogues and Blend Research

GHRP-2 is studied alongside the full ghrelin-mimetic family. GHRP-6, the hexapeptide predecessor to GHRP-2, produces a stronger appetite signal and slightly different GH-to-cortisol ratio, making it a key comparator. Hexarelin, the most potent synthetic GHRP studied to date, provides the upper bound for GHS-R1a stimulation. Mod GRF 1-29, the standard GHRH co-administration partner, is referenced in virtually all GHRP-2 synergy studies. Somatostatin establishes the inhibitory counterweight to GHRP-2 stimulation. Ghrelin is the endogenous comparator at the GHS-R1a receptor.

Common dual-compound blend formulations studied with GHRP-2 include CJC-1295 + GHRP-2, Mod GRF + GHRP-2, and Sermorelin + GHRP-2. Triple-compound formulations include CJC-1295 + GHRP-2 + Ipamorelin and Sermorelin + GHRP-6 + GHRP-2.